PRIMECAP Management acquired 5.45 Million Allogene Therapeutics shares worth $15.1 Million. That's 0.01% of their equity portfolio (236th largest holding). The investor owns 2.93% of the outstanding Allogene Therapeutics stock. The first Allogene Therapeutics trade was made in Q4 2020. Since then PRIMECAP Management bought shares nine more times and sold shares on four occasions. The investor's estimated purchase price is $124 Million, resulting in a loss of 88%.